Backed by a government intent on promoting innovation and fuelled by the "brain gain" of talented scientists and entrepreneurs returning from abroad  China's health biotech industry only needs a more favourable investment climate to emerge as a global force in the production of therapies and medicines - both new and low-cost generics - experts say in a new study